- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00239395
A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With Osteoarthritis
A Randomised, Open-labelled Study to Compare the Efficacy and Safety of Meloxicam 7.5 mg IM Ampoules Once Daily and Meloxicam 7.5 mg Tablets Administered Orally Once Daily Over a Period of 7 Days in Patients With Osteoarthritis (OA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a randomized (1:1), open-label, multi-center, active-control, parallel-group study to compare the efficacy of 7.5 mg meloxicam i.m. once daily compared with 7.5 mg meloxicam tablets once daily p.o. in patients with osteoarthritis over a time period of 7 days.
The primary endpoint: Pain on active movement,
The secondary endpoint:
- Pain at rest
- Patient status with regard to change of arthritic condition assessed by the patient/investigator
- Patient's assessment of arthritic condition
- Onset of action
- Time to maximum pain relief
- Paracetamol consumption
- Withdrawals due to inadequate efficacy
- Final global assessment of efficacy by the patient/investigator
Safety endpoints
- Local tolerability assessment of the injections by the patient/investigator
- Patient's /Investigator's assessment of overall tolerability
- Number, nature and severity of adverse events
- Laboratory investigations
- Withdrawals due to safety reasons
Patients eligible for the trial who met all inclusion and exclusion criteria and who gave their informed consent were randomized to one of two treatment groups (i.e. meloxicam ampoule or meloxicam tablet).
The study period totaled 8-14 days included screening, randomisation, study drug administration, and 7-day follow-up. The relevant assessment were performed on the day of randomisation and 7-day follow up.
Study Hypothesis:
The null hypothesis of interest is that the primary endpoint for meloxicam ampoule is inferior to oral meloxicam. The alternative is that meloxicam ampoule is noninferior to the oral meloxicam .
Comparison(s):
The primary endpoint of the study was to assess pain on active movement by VAS prior and after the treatment.
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100044
- People's Hospital, Beijing University
-
Beijing, China, 100050
- Beijing Xuan Wu Hospital
-
Hefei City, Anhui Province, China, 230022
- 1st Affiliated, Anhui Medical University
-
Nan City, China, 250012
- Qilu Hospital, Shang Dong University
-
Shanghai, China, 200032
- Shanghai Zhongshan Hospital
-
Shanghai, China, 200001
- Shanghai Renji Hospital
-
Shanghai, China, 200052
- Shanghai Guanghai Hospital
-
Shanghai, China, 200443
- Shanghai Changhai Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female aged 18 years or above
- Patients suffering from acute and painful exacerbation of osteoarthritis of the hip or knee.
The diagnosis must be based on
- clinical signs and symptoms or
x-ray diagnosis plus clinical signs and symptoms
- Assessment of pain on active movement (by the patient) must exceed 40 mm on a 100 mm visual analogue scale (VAS)
- Symptoms of OA requiring administration of NSAIDs
- Willingness and ability to provide written informed consent.
Exclusion Criteria:
- Known or suspected hypersensitivity to the trial drugs or their excipients, analgesics, antipyretics or NSAIDs
- Any clinical evidence of active peptic ulceration during the last six months
- Pregnancy or breastfeeding (precaution : attention should be drawn to reports that NSAIDs were reported to decrease the effectivity of intrauterine devices)
- Asthma, nasal polyps, angioneurotic oedema or urticaria following the administration of aspirin or NSAIDs
- Concomitant treatment with anti-coagulants (including heparin), lithium
- Concomitant administration of other NSAIDs or analgesic agents (except paracetamol up to 4g/day)
- Administration of any NSAID during the last 2 days (3 days for any oxicam) prior to the first administration of the trial drug
- Concomitant treatment with an oral corticosteroid initiated or with an altered dose over the previous month
- Parenteral or intraarticular administration of corticosteroids in the previous month
- Any i.m. injection during the previous 7 days
- Any contra-indication to i.m. injections
- Clinical evidence of or known severe cardiac, hepatic, renal, metabolic, haematological disease, mental disturbance, ulcerative colitis
- Any other rheumatological or non-rheumatological disease that could interfere with the evaluation of efficacy and safety
- Serum creatinine 125 % of the upper limit of normal range ; aspartate transferase (AST/SGOT) and/or alkaline transferase (ALT/SGPT) 200 % of the upper limit of normal range
- Platelet count < 100,000/mm3 ; leucocytes count < 3,000/mm3
- Synovectomy in the previous month or during the trial
- Participation in another clinical trial during this study or during the previous month
- Previous participation in this trial
- Patient unable to comply with the protocol
- Concomitant therapy with specific symptomatic drug of OA, such as chondroitin sulphate, diacerhein, initiated or with an altered dose over the previous 3 months.
- Intraarticular administration of hyaluronic acid in the previous month
- Patients where physiotherapy will be changed throughout the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pain on active movement by VAS.
Time Frame: day 0, day 7
|
day 0, day 7
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pain at rest
Time Frame: up to 7 days
|
up to 7 days
|
Patient status with regard to change of arthritic condition
Time Frame: up to 7 days
|
up to 7 days
|
Withdrawals due to inadequate efficacy
Time Frame: up to 7 days
|
up to 7 days
|
Onset of Analgesic action
Time Frame: up to 7 days
|
up to 7 days
|
Time to maximum pain relief
Time Frame: up to 7 days
|
up to 7 days
|
Paracetamol consumption
Time Frame: up to 7 days
|
up to 7 days
|
Final global assessment of efficacy by patient
Time Frame: up to 7 days
|
up to 7 days
|
Final global assessment of efficacy by investigator
Time Frame: up to 7 days
|
up to 7 days
|
Assessment of local tolerability
Time Frame: up to 7 days
|
up to 7 days
|
Nature and severity of adverse events
Time Frame: up to 7 days
|
up to 7 days
|
Change in other laboratory investigations
Time Frame: up to 7 days
|
up to 7 days
|
Withdrawals due to safety reasons
Time Frame: up to 7 days
|
up to 7 days
|
Patient's and investigator's assessment of overall tolerability
Time Frame: up to 7 days
|
up to 7 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Boehringer Ingelheim Study Coordinator, Boehringer Ingelheim Shanghai
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Meloxicam
Other Study ID Numbers
- 107.265
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on Meloxicam ampoule
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Scotmann PharmaceuticalsRawalpindi Medical CollegeNot yet recruiting
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Makerere UniversityCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted